

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CSPC PHARMACEUTICAL GROUP LIMITED,
CSPC OUYI PHARMACEUTICAL CO., LTD., AND
CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioners,
v.

IPSEN BIOPHARM LTD.,
Patent Owner.

Case No. IPR2025-00505
Patent No. 11,344,552

**PETITIONERS' MOTION FOR ADMISSION *PRO HAC VICE*
OF HOWARD S. SUH**

Pursuant to 37 C.F.R. § 42.10 and the Board’s authorization to file motions for *pro hac vice* admission in Inter Partes Review Case No. IPR2025-00505, (see Paper 5 at 3), CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjurpro Biotherapeutics, Inc., (collectively “Petitioners”), request that the Board admit Howard S. Suh *pro hac vice* in this proceeding.

The Board may recognize counsel *pro hac vice* during a proceeding on a showing of good cause. “[W]here lead counsel is a registered practitioner, a motion to appear *pro hac vice* may be granted upon a showing that counsel is an experienced litigation attorney and has an established familiarity with the subject matter at issue in the proceeding.” 37 C.F.R. § 42.10(c).

Here, lead counsel Lukas D. Toft is a registered practitioner (Reg. No. 75,311), and first backup Joe Chen is also a registered practitioner (Reg. No. 70,066). Both Mr. Toft and Mr. Chen practice in the same firm as Mr. Suh. Mr. Suh has years of patent litigation experience, and he is substantially familiar with the subject matter at issue in this proceeding. Accompanying this motion is the Declaration of Howard S. Suh, where Mr. Suh attests to his experience and familiarity. *See generally* Suh Decl. (Ex. 1208). Specifically, Mr. Suh attests that:

- He has been practicing intellectual property litigation for over 25 years, and specifically patent litigation for more than 20 years.
- He has been counsel on over 30 patent litigation cases.

- Howard Suh has been admitted to the Board previously by pro hac vice in at least the following proceedings: (1) *RiceTec v. BASF SE*, PGR2021-00113 and PGR 2021-00113; and (2) *bluebird v. Sloan Kettering Institute and San Rocco Therapeutics*, IPR2023-00070 and IPR2023-00074.

Good cause exists because (1) the Parties anticipate numerous calls with the Board in which Mr. Suh may have insight to provide or argument to assert, (2) the Parties have multiple depositions to take across the country, some of which may need two days to take, and (3) Petitioners anticipates additional discovery or motion practice that would necessitate Mr. Suh's involvement. Mr. Suh's involvement in these proceedings ensures the full team representing Petitioners can appear before the Board. Additionally, this motion and Mr. Suh's declaration meet the other requirements for *pro hac vice* admission in this matter. Moreover, Petitioners have indicated that it will not oppose this motion. Accordingly, these facts establish good cause to recognize Mr. Suh in this proceeding. Thus, Petitioners request that the Board admit Mr. Suh *pro hac vice* in this proceeding.

Case No. IPR2025-00505

Patent No. 11,344,552

Dated: November 24, 2025

By: /s/ Lukas D. Toft

Lukas D. Toft (Reg. No. 75,311)

FOX ROTHSCHILD LLP

33 South Sixth Street, Suite 3600

Minneapolis, MN 55402

Telephone: (612) 607-7000

Facsimile: (612) 607-7100

ltoft@foxrothschild.com

Joe Chen, Ph.D. (Reg. No. 70,066)

FOX ROTHSCHILD LLP

997 Lenox Drive

Lawrenceville, NJ 08648

Telephone: (609) 844-3024

Facsimile: (609) 896-1469

joechen@foxrothschild.com

**Attorneys for CSPC Pharmaceutical Group
Limited, CSPC Ouyi Pharmaceutical Co.,
Ltd., and Conjurpro Biotherapeutics, Inc.**

CERTIFICATE OF SERVICE

Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on May 23, 2023, the foregoing CSPC Pharmaceutical Group Limited, CSPC Ouyi Pharmaceutical Co., Ltd., and Conjurpro Biotherapeutics, Inc., Motion for Admission *Pro Hac Vice* of Howard S. Suh, was served via e-mail, as authorized by the Petitioner, at the following email correspondence address of record:

jimglass@quinnemanuel.com
michaellabas@quinnemanuel.com
anguschen@quinnemanuel.com
quincylu@quinnemanuel.com
elizabethmurphy@quinnemanuel.com
rossmisskelley@quinnemanuel.com

Dated: November 24, 2025

/s/ Lukas D. Toft

Lukas D. Toft (Reg. No. 75,311)
Counsel for CSPC Pharmaceutical Group
Limited, CSPC Ouyi Pharmaceutical Co., Ltd.,
and Conjurpro Biotherapeutics, Inc.